Strengths and Limitations of the Six-Minute-Walk Test A Model Biomarker Study in Idiopathic Pulmonary Fibrosis

[1]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[2]  H. Hoogsteden,et al.  Serum biomarkers in idiopathic pulmonary fibrosis. , 2010, Pulmonary pharmacology & therapeutics.

[3]  R. Dweik,et al.  Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[4]  I. Pavord,et al.  Exhaled nitric oxide in pulmonary diseases: a comprehensive review. , 2010, Chest.

[5]  J. Patrie,et al.  Six‐Minute Walk Distance in Patients With Severe End‐Stage COPD: ASSOCIATION WITH SURVIVAL AFTER INPATIENT PULMONARY REHABILITATION , 2010, Journal of cardiopulmonary rehabilitation and prevention.

[6]  A. Peacock,et al.  The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension , 2010, European Respiratory Journal.

[7]  R. Dweik,et al.  CXC-Chemokine Ligand 10 in Idiopathic Pulmonary Arterial Hypertension: Marker of Improved Survival , 2010, Lung.

[8]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[9]  R. Dweik,et al.  High levels of hyaluronan in idiopathic pulmonary arterial hypertension. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[10]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[11]  R. Hays,et al.  Approaches and Recommendations for Estimating Minimally Important Differences for Health-Related Quality of Life Measures , 2005, COPD.

[12]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[13]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[14]  V. Hasselblad,et al.  Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. , 2001, The American journal of cardiology.

[15]  S. Kesten,et al.  Variability in performance of timed walk tests in pulmonary rehabilitation programs. , 2000, Chest.

[16]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[17]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[18]  A. Woodcock,et al.  Two-, six-, and 12-minute walking tests in respiratory disease. , 1982, British medical journal.

[19]  M. Artvinli,et al.  Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. , 1978, British medical journal.

[20]  S. P. Gupta,et al.  Twelve-minute walking test for assessing disability in chronic bronchitis. , 1976, British medical journal.